Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT03569891
Previous Study | Return to List | Next Study

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03569891
Recruitment Status : Active, not recruiting
First Posted : June 26, 2018
Last Update Posted : March 21, 2022
Information provided by (Responsible Party):
CSL Behring

Brief Summary:

This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profile.

The study drug is identified as AAV5-hFIXco-Padua (AMT- 061). AMT-061 is a recombinant adeno-associated viral vector of serotype 5 (AAV5) containing the Padua variant of a codon-optimized human FIX complementary deoxyribonucleic acid (cDNA) under the control of a liver-specific promoter. The pharmaceutical form of AMT-061 is a solution for intravenous infusion administered at a dose of 2 x 10^13 gc/kg.

Condition or disease Intervention/treatment Phase
Hemophilia B Genetic: AAV5-hFIXco-Padua Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: The reference therapy is prophylactic factor IX replacement therapy used during the lead-in phase prior to treatment with AAV5-hFIXco-Padua (AMT-061).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Actual Study Start Date : June 27, 2018
Actual Primary Completion Date : September 22, 2021
Estimated Study Completion Date : March 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AMT-061

Single infusion of AMT-061

Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After study drug administration (post study drug), subjects will be monitored for tolerance to the study drug and detection of potential immediate AEs at the clinical trial site for a few hours after dosing.

Genetic: AAV5-hFIXco-Padua
Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
Other Name: AMT-061

Primary Outcome Measures :
  1. Annualized bleeding rate (ABR) [ Time Frame: 52 weeks following stable factor IX expression (months 6-18 post-treatment) ]
    Comparison of ABR between prophylaxis used in the lead-in and after administration of AMT-061

Secondary Outcome Measures :
  1. Factor IX activity levels [ Time Frame: 26 weeks, 52 weeks and 18 months after AMT-061 dosing ]
    Endogenous factor IX activity at 26 weeks, 52 weeks and 18 months after AMT-061 dosing

  2. Use of factor IX replacement therapy [ Time Frame: 52 weeks following stable factor IX expression (months 6-18 post-treatment) ]
    Patients will record all use of prophylactic factor IX replacement therapy in a diary, including reason for factor IX use, date, and time of infusion and total dose

  3. Adverse events [ Time Frame: 5 years ]
    Follow up and assess any adverse events reported for safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male
  2. Age ≥18 years
  3. Subjects with congenital hemophilia B, classified as severe or moderately severe, and are currently on factor IX prophylaxis
  4. >150 previous exposure days of treatment with factor IX protein

Exclusion Criteria:

  1. History of factor IX inhibitors
  2. Positive factor IX inhibitor test at screening
  3. Select screening laboratory value >2 times upper limit of normal
  4. Positive human immunodeficiency virus (HIV) test at screening, not controlled with anti-viral therapy
  5. Active infection with hepatitis B or C virus at screening
  6. History of Hepatitis B or C exposure, currently controlled by antiviral therapy at the end of the lead-in phase
  7. Previous gene therapy treatment
  8. Receipt of an experimental agent within 60 days prior to screening
  9. Current participation or anticipated participation within one year after study drug administration in this trial in any other interventional clinical trial involving drugs or devices

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03569891

Show Show 35 study locations
Sponsors and Collaborators
CSL Behring
Layout table for investigator information
Principal Investigator: Steven Pipe, MD University of Michigan
Layout table for additonal information
Responsible Party: CSL Behring Identifier: NCT03569891    
Other Study ID Numbers: CSL222_3001 (CT-AMT-061-02)
First Posted: June 26, 2018    Key Record Dates
Last Update Posted: March 21, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CSL Behring:
Gene therapy
factor IX
Viral vector
AAV (adeno-associated virus)
serotype 5 AAV (adeno-associated virus)
serotype 5
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked